Flash Finance

Nureca LimitedNURECACorporate

Medical Equipment & Supplies Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹320.85
MCap ₹321 Cr · P/E 147.6
Nureca Limited — Stock analysis & AI research Nureca Limited — Multibagger AI analysis Nureca Limited — Seasonality — best & worst months Nureca Limited — Technical setup — score, trend, support & resistance Nureca Limited — Live exchange announcements
🏭 Healthcare sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹40 Cr
Sales · Jun 2026
+17.7% YoY
₹2 Cr
Operating Profit · Jun 2026
+326.7% YoY
6.1%
OPM % · Jun 2026
+296.8% YoY
₹2 Cr
Net Profit · Jun 2026
+340.6% YoY
₹2.55
EPS · Jun 2026
+363.6% YoY

📝 Nureca Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Nureca Limited reported revenue of ₹40 crore for the quarter ended June 2026 (Q1 FY27), up 17.7% from ₹34 crore in the same quarter last year, and up 14.1% sequentially over the March 2026 quarter.

Net profit rose 340.6% year-on-year to ₹2 crore, from ₹1 crore. Earnings per share (EPS) came in at ₹2.55.

Operating profit stood at ₹2 crore — an operating margin (OPM) of 6.1%, compared with -3.1% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Nureca Limited posted revenue of ₹147 crore, a growth of 28.4% over FY25, with a net profit of ₹0 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹153 crore with a net profit of ₹2 crore.

Valuation snapshot

At the current price of ₹320.85, NURECA has a market capitalisation of ₹321 crore and a trailing P/E of about 147.6.

Within the Medical Equipment & Supplies industry, it is the 7th-largest of the 13 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 68.09%, foreign institutional investors (FIIs) 0.11%, domestic institutional investors (DIIs) 0.24%, public shareholders 31.57% of Nureca Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹321 Cr
Current Price ?
₹320.9
P/E ?
147.63above ind
Industry P/E ?
26.90
P/B ?
1.80
P/S ?
2.09
P/FCF ?
-64.16
Enterprise Value ?
₹323 Cr
EV/EBITDA ?
351.25
PEG ?
5.47
Earnings Yield ?
-0.3%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹153 Cr
OPM ?
0.6%
Profit after tax (TTM) ?
₹2 Cr
EPS (TTM) ?
₹2.17
ROCE ?
2.0%
ROE ?
1.2%
ROA ?
1.1%
Growth
Sales — latest qtr ?
₹40 Cr
PAT — latest qtr ?
₹2 Cr
YoY qtr sales growth ?
17.7%
YoY qtr profit growth ?
340.6%
Sales growth (3y) ?
10%
Sales growth (5y) ?
-7%
Profit growth (3y) ?
27%
Profit growth (5y) ?
-64%
Financial Health
Debt ?
₹2 Cr
Debt to Equity ?
0.01
Interest Coverage ?
-4.3
Current Ratio ?
N/A
Ownership
Promoter holding ?
68.09%
Change in promoter holding ?
3.76%
Pledged percentage ?
N/A
Market
Return 3 months ?
14.7%
Return 6 months ?
21.6%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 2821213142220233227323438403540 +17.7% +14.1%
Operating Profit -1-4-310-4-5-3-3-51-132-72 +326.7% +137.4%
Other Income 223326-1632232212 -26.0% +80.9%
Interest 000100000100000 -12.4% -26.2%
Depreciation 111611110000001 +18.2% +31.6%
Profit Before Tax 0-2-1361-72-0-41144-64 +334.5% +158.8%
Net Profit 0-2-1260-41-1-32133-72 +340.6% +136.7%
EPS 0.03-1.80-0.742.640.08-4.411.19-0.65-3.292.070.553.143.39-6.952.55 +363.6% +136.7%
OPM % -4.5% -18.0% -14.1% 3.3% -19.8% -24.3% -12.5% -8.2% -17.4% 1.8% -3.1% 6.9% 6.0% -18.5% 6.1% +296.8% +133.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹115 Cr ₹147 Cr ₹153 Cr +28.4%
Operating Profit ₹-10 Cr ₹-3 Cr ₹1 Cr +73.3%
OPM % -8.49% -1.77% 0.60% +79.2%
NPM % -0.58% 0.20% 1.42% +134.5%
Other Income ₹13 Cr ₹8 Cr ₹8 Cr -33.7%
Depreciation ₹2 Cr ₹2 Cr ₹2 Cr -14.4%
Interest ₹1 Cr ₹1 Cr ₹1 Cr -7.7%
EBIT ₹-12 Cr ₹-4 Cr ₹-1 Cr +62.6%
PBT ₹-0 Cr ₹3 Cr ₹6 Cr +717.6%
Tax ₹0 Cr ₹1 Cr ₹2 Cr +427.9%
Net Profit ₹-1 Cr ₹0 Cr ₹2 Cr +143.9%
EPS ₹-0.68 ₹0.13 ₹2.13 +119.1%
Material Cost ₹86 Cr ₹64 Cr ₹59 Cr -26.4%
Employee Cost ₹14 Cr ₹8 Cr ₹8 Cr -44.4%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 10101010 +0.0%
Reserves 185183182168 -7.7%
Borrowings 3242 -50.0%
Other Liabilities 891014 +40.0%
Total Liabilities 207204206194 -5.8%
Fixed Assets 86812 +50.0%
CWIP 0000 —
Investments 629744 +0.0%
Other Assets 136101194177 -8.8%
Total Assets 207204206194 -5.8%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 12-3-190 +100.0%
Cash from Investing Activity -1818916 +77.8%
Cash from Financing Activity -2-1-1-19 -1800.0%
Net Cash Flow -814-11-2 +81.8%
Free Cash Flow 12-4-20-5 +75.0%
CFO/OP -107%40%180%4% -97.8%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 1471424 +71.4%
Inventory Days 154156163162 -0.6%
Days Payable 23272623 -11.5%
Cash Conversion Cycle 145136151164 +8.6%
Working Capital Days 148160403135 -66.5%
ROCE % -5%-1%0%2% —

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 64.33%64.97%64.97%68.09%68.09% +0.0%
FIIs 0.07%0.07%0.08%0.28%0.11% -60.7%
DIIs 0.04%0.04%0.04%0.24%0.24% +0.0%
Public 35.56%34.92%34.91%31.39%31.57% +0.6%
No. of Shareholders 38,07537,46835,80134,55833,979 -1.7%

⚖️ Peer comparison

Industry: Medical Equipment & Supplies · 13 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 FISCHER Fischer Medical ₹33.50 2,293 85.2 367 24 12.3% 6.7% 178.6% 2051.4% 249.4% -24.3%
2 TARSONS Tarsons Products ₹330.00 1,756 157.9 441 11 27.0% 2.5% -66.3% -81.4% 20.7% -181.0%
3 DENTALKART Vasa Denticity ₹563.10 977 80.0 299 12 4.4% 4.0% 16.7% -28.5% 12.9% -2.9%
4 543916 Hemant Surgical ₹193.85 544 13.9 231 18 10.4% 7.8% — — 187.9% 160.0%
5 543363 Prevest Denpro ₹616.50 456 32.8 75 23 35.7% 29.9% 13.6% 17.6% 23.7% 24.8%
6 QMSMEDI QMS Medical ₹185.89 359 52.7 162 7 13.1% 4.1% 5.1% -47.9% 23.7% -0.8%
7 NURECA Nureca ₹331.55 331 75.9 153 4 2.7% 2.8% 34.0% 146.7% 18.0% 277.2%
8 530427 Choksi Asia ₹65.64 122 7.2 47 5 14.5% 11.1% 61.1% 173.2% -22.5% -10.1%
9 527005 Shree Pacetronix ₹168.25 55 19.2 21 3 24.8% 15.3% 28.7% 324.3% -8.3% 14.5%
10 544143 Royal Sense ₹139.00 47 24.7 38 3 12.8% 8.0% — — 2.5% -5.4%
11 533212 GKB Ophthalmics ₹104.90 32 17.6 150 6 7.0% 3.7% 36.8% 142.7% 2.3% 388.5%
12 531380 Centenial Surgical ₹110.90 27 — 56 -1 10.7% -2.6% 0.6% -38.1% 18.6% 1937.8%
13 542765 Transpact Enterprises ₹325.00 4 140.1 0 0 63.2% 47.4% — — 12.5% -20.0%
❓ Frequently asked questions
What was Nureca Limited's revenue in Q1 FY27?
Nureca Limited reported revenue of ₹40 crore for the quarter ended June 2026 (Q1 FY27), up 17.7% from ₹34 crore in the same quarter last year, and up 14.1% sequentially over the March 2026 quarter.
What was Nureca Limited's net profit in Q1 FY27?
Net profit rose 340.6% year-on-year to ₹2 crore, from ₹1 crore. Earnings per share (EPS) came in at ₹2.55.
What is NURECA's market capitalisation and P/E ratio?
At the current price of ₹320.85, NURECA has a market capitalisation of ₹321 crore and a trailing P/E of about 147.6.
Who owns Nureca Limited? (shareholding pattern)
As of Jun 2026, promoters held 68.09%, foreign institutional investors (FIIs) 0.11%, domestic institutional investors (DIIs) 0.24%, public shareholders 31.57% of Nureca Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI